Implications of proprotein convertases in ovarian cancer cell proliferation and tumor progression: Insights for pace4 as a therapeutic target

Translational Oncology

Volumn 7, Issue 3, 2014, Pages 410-419

  Longuespée, Rémi ^a,b   Couture, Frédéric ^b   Levesque, Christine ^b   Kwiatkowska, Anna ^b   Desjardins, Roxane ^b   Gagnon, Sandra ^b   Vergara, Daniele ^a,c   Maffia, Michelle ^c   Fournier, Isabelle ^a   Salzet, Michel ^a   Day, Robert ^b  

^a UNIV LILLE   (France)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c ASL Lecce   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FURIN; PACE 4 INHIBITOR; PEPTIDOMIMETIC AGENT; PROPROTEIN CONVERTASE 1; PROPROTEIN CONVERTASE 2; PROPROTEIN CONVERTASE 5; PROTEIN INHIBITOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL GROWTH ASSAY; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CLONOGENESIS; COLORIMETRY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; GENETIC TRANSDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN EXPRESSION ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 85002198103     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.04.008     Document Type: Article

References (42)

1. Longuespée R, Boyon C, Desmons A, Vinatier D, Leblanc E, Farré I, Wisztorski M, Ly K, D'Anjou F, and Day R, et al (2012). Ovarian cancer molecular pathology. Cancer Metastasis Rev 31, 713–732.
2. Khatib AM, Siegfried G, Chrétien M, Metrakos P, and Seidah NG (2002). Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 160, 1921–1935.
3. Couture F, D'Anjou F, and Day R (2011). On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications. Biomol Concepts 2, 421–438.
4. Fugère M and Day R (2005). Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition. Trends Pharmacol Sci 26, 294–301.
5. Cheng M, Watson PH, Paterson JA, Seidah N, Chrétien M, and Shiu RP (1997). Pro-protein convertase gene expression in human breast cancer. Int J Cancer 71, 966–971.
6. Bassi DE, Mahloogi H, Al-Saleem L, Lopez De Cicco R, Ridge JA, and Klein- Szanto AJ (2001). Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog 31, 224–232.
7. D'Anjou F, Routhier S, Perreault JP, Latil A, Bonnel D, Fournier I, Salzet M, and Day R (2011). Molecular validation of PACE4 as a target in prostate cancer. Transl Oncol 4, 157–172.
8. Juliano RL and Haskill S (1993). Signal transduction from the extracellular matrix. J Cell Biol 120, 577–585.
9. Fu Y, Campbell EJ, Shepherd TG, and Nachtigal MW (2003). Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. Mol Cancer Res 1, 569–576.
10. Page RE, Klein-Szanto AJ, Litwin S, Nicolas E, Al-Jumaily R, Alexander P, Godwin AK, Ross EA, Schilder RJ, and Bassi DE (2007). Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol 29, 289–299.
11. Couture F, D'Anjou F, Desjardins R, Boudreau F, and Day R (2012). Role of proprotein convertases in prostate cancer progression. Neoplasia 14, 1032–1042.
12. D'Anjou F, Couture F, Desjardins R, and Day R (2014). Knockdown strategies for the study of proprotein convertases and proliferation in prostate cancer cells. Methods Mol Biol 1103, 67–82.
13. Pham NA, Morrison A, Schwock J, Aviel-Ronen S, Iakovlev V, Tsao MS, Ho J, and Hedley DW (2007). Quantitative image analysis of immunohistochemical stains using a CMYK color model. Diagn Pathol 2, 8.
14. Kwiatkowska A, Couture F, Levesque C, Ly K, Desjardins R, Beauchemin S, Prahl A, Lammek B, Neugebauer W, and Dory YL, et al (2014). Design, synthesis, and structure–activity relationship studies of a potent PACE4 inhibitor. J Med Chem 57, 98–109.
15. Levesque C, Fugère M, Kwiatkowska A, Couture F, Desjardins R, Routhier S, Moussette P, Prahl A, Lammek B, and Appel JR, et al (2012). The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells. J Med Chem 55, 10501–10511.
16. Roehm NW, Rodgers GH, Hatfield SM, and Glasebrook AL (1991). An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods 142, 257–265.
17. Vollenweider F, Benjannet S, Decroly E, Savaria D, Lazure C, Thomas G, Chrétien M, and Seidah NG (1996). Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 by the mammalian subtilisin/kexin-like convertases. Biochem J 314, 521–532.
18. Sundfeldt K (2003). Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Mol Cell Endocrinol 202, 89–96.
19. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, and Kenny HA, et al (2008). Loss of Ecadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target. Cancer Res 68, 2329–2339.
20. Siegel R, Naishadham D, and Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin 63, 11–30.
21. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, and Bray F (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49, 1374–1403.
22. Lindert AC, Barents JW, and Pinedo HM (1978). The silent killer: treatment of a patient by the oncological team. Ned Tijdschr Geneeskd 122, 65–68.
23. Seidah NG and Prat A (2012). The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11, 367–383.
24. Dong LL, Liu L, Ma CH, Li JS, Du C, Xu S, Han LH, Li L, and Wang XW (2012). E-cadherin promotes proliferation of human ovarian cancer cells in vitro via activating MEK/ERK pathway. Acta Pharmacol Sin 33, 817–822.
25. De Marzo AM, Knudsen B, Chan-Tack K, and Epstein JI (1999). E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 53, 707–713.
26. Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktaş M, Hwang MS, Darling DS, Coleman IM, and Nelson PS, et al (2011). Metastatic progression of prostate cancer and e-cadherin: regulation by Zeb1 and Src family kinases. Am J Pathol 179, 400–410.
27. Lewis-Tuffin LJ, Rodriguez F, Giannini C, Scheithauer B, Necela BM, Sarkaria JN, and Anastasiadis PZ (2010). Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One 5, e13665.
28. Samir R, Asplund A, Tot T, Pekar G, and Hellberg D (2011). High-risk HPV infection and CIN grade correlates to the expression of c-myc, CD4+, FHIT, E-cadherin, Ki-67, and p16INK4a. J Low Genit Tract Dis 15, 280–286.
29. Estilo CL, O-charoenrat P, Talbot S, Socci ND, Carlson DL, Ghossein R, Williams T, Yonekawa Y, Ramanathan Y, and Boyle JO, et al (2009). Oral tongue cancer gene expression profiling: identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer 9, 11.
30. Kurokawa Y, Matoba R, Nakamori S, Takemasa I, Nagano H, Dono K, Umeshita K, Sakon M, Monden M, and Kato K (2004). PCR-array gene expression profiling of hepatocellular carcinoma. J Exp Clin Cancer Res 23, 135–141.
31. Delic S, Lottmann N, Jetschke K, Reifenberger G, and Riemenschneider MJ (2012). Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated candidate genes. Neuropathol Appl Neurobiol 38, 201–212.
32. Bassi DE, Lopez De Cicco R, Cenna J, Litwin S, Cukierman E, and Klein-Szanto AJ (2005). PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. Cancer Res 65, 7310–7319.
33. Mahloogi H, Bassi DE, and Klein-Szanto AJ (2002). Malignant conversion of nontumorigenic murine skin keratinocytes overexpressing PACE4. Carcinogenesis 23, 565–572.
34. Mujoomdar ML, Hogan LM, Parlow AF, and Nachtigal MW (2011). Pcsk6 mutant mice exhibit progressive loss of ovarian function, altered gene expression, and formation of ovarian pathology. Reproduction 141, 343–355.
35. Fugère M and Day R (2002). Inhibitors of the subtilase-like pro-protein convertases (SPCs). Curr Pharm Des 8, 549–562.
36. Kurman RJ and Shih Ie M (2010). The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34, 433–443.
37. Longuespée R, Gagnon H, Boyon C, Strupat K, Dauly C, Kerdraon O, Ighodaro A, Desmons A, Dupuis J, and Wisztorski M, et al (2013). Proteomic analyses of serous and endometrioid epithelial ovarian cancers – cases studies – molecular insights of a possible histological etiology of serous ovarian cancer. Proteomics Clin Appl 7, 337–354.
38. Kleifeld O, Doucet A, auf dem Keller U, Prudova A, Schilling O, Kainthan RK, Starr AE, Foster LJ, Kizhakkedathu JN, and Overall CM (2010). Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products. Nat Biotechnol 28, 281–288.
39. El Ayed M, Bonnel D, Longuespée R, Castelier C, Franck J, Vergara D, Desmons A, Tasiemski A, Kenani A, and Vinatier D, et al (2010). MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers. Med Sci Monit 16, BR 233–245.
40. Calligaris D, Longuespée R, Debois D, Asakawa D, Turtoi A, Castronovo V, Noël A, Bertrand V, De Pauw-Gillet MC, and De Pauw E (2013). Selected protein monitoring in histological sections by targeted MALDI-FTICR in-source decay imaging. Anal Chem 85, 2117–2126.
41. Longuespée R, Boyon C, Castellier C, Jacquet A, Desmons A, Kerdraon O, Vinatier D, Fournier I, Day R, and Salzet M (2012). The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumorrelapse biomarker: evidence from mass spectrometry profiling. Histochem Cell Biol 138, 141–154.
42. Franck J, Longuespée R, Wisztorski M, Van Remoortere A, Van Zeijl R, Deelder A, Salzet M, McDonnell L, and Fournier I (2010). MALDI mass spectrometry imaging of proteins exceeding 30,000 daltons. Med Sci Monit 16, BR 293–99.